Praxis Precision Medicines Inc expected to post a loss of $3.66 a share - Earnings Preview

Praxis Precision Medicines

04/08/2026 14:18

Praxis Precision Medicines Inc PRAX.OQ PRAX.O is expected to  show no change in quarterly revenue when it reports  results on August 6 for the period ending June 30 2026

​LSEG's mean analyst estimate for Praxis Precision Medicines Inc is for a loss of $3.66 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Praxis Precision Medicines Inc is $550.00, about 80% above its last closing price of $305.51
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-3.50
-3.55
-3.20
Beat
9.8
Dec. 31 2026
-3.08
-3.10
-3.50
Missed
-12.9
Sep. 30 2025
-3.45
-3.44
-3.36
Beat
2.4​
Jun. 30 2025
-3.28
-3.33
-3.31
Beat
0.6
​​Mar. 31 2025
-3.21
-3.20
-3.29
Missed
-2.8
Dec. 31 2024
-2.82
-2.85
-2.94
Missed
-3.3​
Sep. 30 2024
-1.97
-1.99
-2.75
Missed
-38.3
Jun. 30 2024
-2.26
-2.31
-1.74
Beat
24.8
This summary was machine generated August 4 at 13:18 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)